Key result
The overall prevalence of metabolic syndrome among depressed patients was 35%, with no significant difference between those on antidepressants and drug-naive patients.
Why the study?
While research from the West suggests a direct link between depression and metabolic syndrome, there is a scarcity of literature supporting these data from the East.
Does antidepressant medication use increase the prevalence of metabolic syndrome in patients with depressive disorder?
Cross-Sectional (n=60)
No
Does antidepressant medication use increase the prevalence of metabolic syndrome in patients with depressive disorder?
More than a third of patients with depression meet criteria for metabolic syndrome, highlighting the importance of regular metabolic screening in this population irrespective of antidepressant use.
Answers are grounded in this paper and cite their sources.
Metabolic screening merits consideration in all depressed patients; cross-sectional data leaves open independent antidepressant effects and requires prospective validation.
Background: Depression is a leading cause of disability worldwide and is also known to be comorbid with a number of medical and psychiatric illnesses. Metabolic syndrome (MS) that is now emerging as a common lifestyle illness is found to be twofold greater in patients with depression. Often, antidepressants have been considered to be the reason for this possible link, however, research from the West suggests that a direct link is plausible. There is a scarcity of literature supporting these data from the East. In this study, we have attempted to assess the prevalence of MS in depressive patients, and to determine the probable risk factors contributing to the association. Materials and methods: Sixty consecutive patients that fulfilled the inclusion criteria were recruited from a tertiary care center in India. Sociodemographic and clinical data were obtained using a semistructured pro forma. Depressive disorder was diagnosed using International classification of diseases-10 (ICD-10), and severity was measured using Hamilton rating scale for depression (HAM-D). The weight, height, waist circumference (WC), systolic and diastolic blood pressure (BP), as well as fasting lipids and glucose were measured. Metabolic syndrome was diagnosed based on National Cholesterol Education Program/Adult Treatment Panel (NCEP ATP-III) criteria (2005 revision). The descriptive and inferential statistics were done using statistical package for social sciences (SPSS) 16.
No takes yet. Share an insight, caveat, or question.
Prakash et al. (2023) conducted a cross-sectional in Depressive disorder (n=60). Antidepressant medication vs. Drug-naive (no antidepressant use) was evaluated on Metabolic syndrome prevalence (NCEP ATP-III criteria) (p=0.294). The overall prevalence of metabolic syndrome among depressed patients was 35%, with no significant difference between those on antidepressants and drug-naive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: